Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab with chemoradiation in stage III non-small cell lung cancer
2006-004945-40Phase 2Terminated
- Sponsor
- Genmab
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zalutumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genmab. Primary endpoint: Progression-free survival. Started Nov 2006; status: terminated.
02
Drugs
zalutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-004945-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004945-40.